Cencora, Inc.

NYSE:COR Stock Report

Market Cap: US$60.8b

Cencora Valuation

Is COR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of COR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: COR ($312.45) is trading below our estimate of future cash flow value ($601.42)

Significantly Below Future Cash Flow Value: COR is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COR?

Key metric: As COR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COR. This is calculated by dividing COR's market cap by their current earnings.
What is COR's PE Ratio?
PE Ratio37.4x
EarningsUS$1.63b
Market CapUS$60.78b

Price to Earnings Ratio vs Peers

How does COR's PE Ratio compare to its peers?

The above table shows the PE ratio for COR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.4x
CAH Cardinal Health
29.2x12.81%US$48.6b
MCK McKesson
24.3x11.22%US$105.4b
HSIC Henry Schein
20.8x12.66%US$8.3b
ELV Elevance Health
11.2x8.24%US$63.2b
COR Cencora
37.4x15.98%US$60.8b

Price-To-Earnings vs Peers: COR is expensive based on its Price-To-Earnings Ratio (37.4x) compared to the peer average (21.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does COR's PE Ratio compare vs other companies in the US Healthcare Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
0.8x-117.81%US$382.85m
NIVF NewGenIvf Group
0.06x44.27%US$1.06m
MDCE Medical Care Technologies
2.4xn/aUS$678.46k
IMTH AnTix Holdings
0.09xn/aUS$108.15k
COR 37.4xIndustry Avg. 21.7xNo. of Companies9PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COR is expensive based on its Price-To-Earnings Ratio (37.4x) compared to the US Healthcare industry average (20.9x).

Price to Earnings Ratio vs Fair Ratio

What is COR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.4x
Fair PE Ratio36.8x

Price-To-Earnings vs Fair Ratio: COR is expensive based on its Price-To-Earnings Ratio (37.4x) compared to the estimated Fair Price-To-Earnings Ratio (36.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$312.45
US$407.92
+30.55%
6.41%US$447.00US$340.00n/a12
Mar ’27US$372.14
US$405.62
+9.00%
6.51%US$440.00US$340.00n/a13
Feb ’27US$359.22
US$399.07
+11.09%
7.46%US$440.00US$315.00n/a15
Jan ’27US$337.75
US$387.93
+14.86%
7.74%US$420.00US$315.00n/a15
Dec ’26US$360.12
US$384.79
+6.85%
8.45%US$417.00US$300.00n/a14
Nov ’26US$337.81
US$336.14
-0.49%
7.74%US$380.00US$274.00n/a14
Oct ’26US$311.77
US$332.86
+6.76%
6.72%US$355.00US$274.00n/a14
Sep ’26US$291.61
US$333.29
+14.29%
6.67%US$355.00US$274.00n/a14
Aug ’26US$288.35
US$329.07
+14.12%
7.53%US$355.00US$260.00n/a14
Jul ’26US$295.33
US$323.16
+9.42%
9.27%US$355.00US$257.45n/a15
Jun ’26US$291.24
US$317.23
+8.92%
10.60%US$355.00US$257.45n/a15
May ’26US$290.43
US$297.49
+2.43%
9.24%US$335.00US$242.00n/a15
Apr ’26US$277.41
US$281.09
+1.33%
6.32%US$308.00US$242.00n/a15
Mar ’26US$253.54
US$278.16
+9.71%
7.03%US$308.00US$242.00US$372.1415
Feb ’26US$254.21
US$270.81
+6.53%
7.84%US$305.00US$230.00US$359.2215
Jan ’26US$224.68
US$266.34
+18.54%
8.34%US$302.00US$230.00US$337.7515
Dec ’25US$251.55
US$266.14
+5.80%
7.71%US$292.00US$230.00US$360.1215
Nov ’25US$234.27
US$257.32
+9.84%
7.57%US$287.00US$215.00US$337.8116
Oct ’25US$224.23
US$259.92
+15.92%
7.51%US$287.00US$215.00US$311.7716
Sep ’25US$239.57
US$262.05
+9.38%
7.53%US$287.00US$215.00US$291.6116
Aug ’25US$244.46
US$260.98
+6.76%
7.70%US$287.00US$215.00US$288.3516
Jul ’25US$223.53
US$255.98
+14.52%
9.00%US$280.00US$194.00US$295.3316
Jun ’25US$226.57
US$255.33
+12.70%
9.27%US$280.00US$194.00US$291.2415
May ’25US$229.20
US$254.84
+11.19%
8.61%US$280.00US$194.00US$290.4316
Apr ’25US$243.00
US$247.84
+1.99%
10.40%US$270.00US$183.00US$277.4116
Mar ’25US$237.03
US$247.00
+4.21%
10.69%US$270.00US$183.00US$253.5415
US$407.92
Fair Value
23.4% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/29 08:44
End of Day Share Price 2026/03/27 00:00
Earnings2025/12/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cencora, Inc. is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Eric ColdwellBaird
Glen SantangeloBarclays